Metformina Pensa (Metformin Hydrochloride)

Metformin lowers blood glucose mainly by inhibiting hepatic gluconeogenesis through activation of AMP‑activated protein kinase (AMPK). It also increases peripheral insulin sensitivity, enhancing glucose uptake in muscle and fat tissue, and reduces intestinal glucose absorption, all without stimulating insulin secretion.

The specific dose of Metformina Pensa is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Metformin crosses the placenta and is classified as a pregnancy‑category drug only when the potential benefit outweighs the risk. It may be continued in pregnancy for certain indications under medical supervision. Limited data exist for breastfeeding, and a clinician should evaluate safety on a case‑by‑case basis.

To request Metformina Pensa, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, metformin (Metformina Pensa) does not stimulate insulin release, resulting in a lower risk of hypoglycaemia and often promotes modest weight loss. It is generally recommended as first‑line therapy for type 2 diabetes because of its efficacy, safety profile and cardiovascular benefits.

Metformina Pensa should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in the bathroom or near heat sources.

Metformina Pensa is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and should not crush or chew the tablets unless specifically instructed.

The most serious adverse reactions include lactic acidosis, a rare but potentially fatal metabolic disturbance, and severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Long‑term therapy may also lead to vitamin B12 deficiency, which should be monitored periodically.

Metformina Pensa is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, and in those with significant hepatic disease. Caution is also advised for patients with a history of alcohol abuse or conditions predisposing to hypoxia.